Letrozol (Femara), novyi ingibitor aromatazy dlia lecheniia bol'nykh rasprostranennym rakom molochnoi zhelezy.

Translated title of the contribution: Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer

M. Gershanovich, K. Chaudri, D. Campos, H. Lurie, A. Bonaventura, M. Jeffrey, F. Buzzi, I. Bodrogi, H. Ludwig, P. Reichard, N. O. O'Higgins, G. Romieu, P. Friedrich, M. Lassus

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens. 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicenter trial. The primary end-point was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrollment of the last patient, while survival was analysed 15 months after the last patients was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Overall objective response rates (complete + partial) of 19.5%, 16.7% and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-estrogens.

Translated title of the contributionLetrozole (Femara), a new aromatase inhibitor for advanced breast cancer
Original languageRussian
Pages (from-to)361-368
Number of pages8
JournalVoprosy onkologii
Volume45
Issue number4
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Gershanovich, M., Chaudri, K., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichard, P., O'Higgins, N. O., Romieu, G., Friedrich, P., & Lassus, M. (1999). Letrozol (Femara), novyi ingibitor aromatazy dlia lecheniia bol'nykh rasprostranennym rakom molochnoi zhelezy. Voprosy onkologii, 45(4), 361-368.